| Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 |
---|
Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
---|
Research and Development Expense | 11 | 29 | 42 | 56 | 50 | 64 | 196 | 248 |
---|
Selling, General and Administrative Expense | 228 | 95 | 57 | 43 | 18 | 27 | 135 | 103 |
---|
Impairment of intangible assets | - | - | - | - | - | - | - | 1 |
---|
Total operating expenses | - | 125 | 99 | 98 | 68 | 92 | 331 | 352 |
---|
Loss from operations | - | -124 | -99 | -98 | -68 | -92 | -330 | -351 |
---|
Gain (Loss) on Investments | - | - | - | - | - | - | -4 | -3 |
---|
Interest expense (including amounts with related parties) | - | 0 | 1 | - | - | - | 15 | 64 |
---|
Loss on equity method investment | -0 | - | - | - | - | - | -1 | -12 |
---|
Change in fair value of warrant liability | 1 | - | - | - | - | - | - | -13 |
---|
Other Nonoperating Income (Expense) | 0 | 0 | 0 | 0 | 0 | -1 | 0 | -1 |
---|
Total other expense, net | - | 3 | 2 | 2 | 2 | -1 | -20 | -66 |
---|
Loss before income taxes and noncontrolling interests | - | -121 | -97 | -97 | -66 | -92 | -350 | -417 |
---|
Income tax (expense) benefit | -0 | -1 | -0 | -1 | -0 | 0 | 0 | 0 |
---|
Net loss | - | - | - | -96 | -66 | -92 | -350 | -417 |
---|
Net Income (Loss) Attributable to Noncontrolling Interest | - | - | - | - | - | - | -3 | -1 |
---|
Net loss attributable to ImmunityBio common stockholders | -237 | -121 | -96 | -96 | -66 | -92 | -347 | -417 |
---|
Earnings Per Share, Basic | - | - | - | - | - | - | -0.89 | -1.04 |
---|
Earnings Per Share, Diluted | - | - | - | - | - | - | -0.89 | -1.04 |
---|